Literature DB >> 32777641

Synthesis of 2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide and 3-oxo-3,4-dihydrobenzo[b][1,4]oxazine-8-carboxamide derivatives as PARP1 inhibitors.

Xuwei Shao1, Steven Pak1, Uday Kiran Velagapudi1, Shruthi Gobbooru1, Sai Shilpa Kommaraju1, Woon-Kai Low1, Gopal Subramaniam2, Sanjai Kumar Pathak3, Tanaji T Talele4.   

Abstract

Poly(ADP-ribose) polymerase 1 (PARP1), a widely explored anticancer drug target, plays an important role in single-strand DNA break repair processes. High-throughput virtual screening (HTVS) of a Maybridge small molecule library using the PARP1-benzimidazole-4-carboxamide co-crystal structure and pharmacophore model led to the identification of eleven compounds. These compounds were evaluated using recombinant PARP1 enzyme assay that resulted in the acquisition of three PARP1 inhibitors: 3 (IC50 = 12 μM), 4 (IC50 = 5.8 μM), and 10 (IC50 = 0.88 μM). Compound 4 (2,3-dihydro-1,4-benzodioxine-5-carboxamide) was selected as a lead and was subjected to further chemical modifications, involving analogue synthesis and scaffold hopping. These efforts led to the identification of (Z)-2-(4-hydroxybenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide (49, IC50 = 0.082 μM) as the most potent inhibitor of PARP1 from the series.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  1,4-benzodioxine; 1,4-benzoxazin-3-one; Knoevenagel condensation; PARP1; Virtual screening

Mesh:

Substances:

Year:  2020        PMID: 32777641      PMCID: PMC8142146          DOI: 10.1016/j.bioorg.2020.104075

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.307


  24 in total

1.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results.

Authors:  Steven L Dixon; Alexander M Smondyrev; Eric H Knoll; Shashidhar N Rao; David E Shaw; Richard A Friesner
Journal:  J Comput Aided Mol Des       Date:  2006-11-24       Impact factor: 3.686

2.  Synthesis of novel 1,4-benzoxazin-3-one derivatives as inhibitors against tyrosine kinases.

Authors:  Takahiro Honda; Takahiro Terao; Hiroyuki Aono; Masakazu Ban
Journal:  Bioorg Med Chem       Date:  2008-12-06       Impact factor: 3.641

3.  Synthesis and SAR optimization of quinazolin-4(3H)-ones as poly(ADP-ribose)polymerase-1 inhibitors.

Authors:  Shridhar S Kulkarni; Satyakam Singh; Janki R Shah; Woon-Kai Low; Tanaji T Talele
Journal:  Eur J Med Chem       Date:  2012-02-09       Impact factor: 6.514

4.  1-(1-phenethylpiperidin-4-yl)-1-phenylethanols as potent and highly selective 5-HT2A antagonists.

Authors:  Timo Heinrich; Henning Böttcher; Helmut Prücher; Rudolf Gottschlich; Karl-August Ackermann; Christoph van Amsterdam
Journal:  ChemMedChem       Date:  2006-02       Impact factor: 3.466

5.  PARP3 comes to light as a prime target in cancer therapy.

Authors:  José Manuel Rodriguez-Vargas; Léonel Nguekeu-Zebaze; Françoise Dantzer
Journal:  Cell Cycle       Date:  2019-05-29       Impact factor: 4.534

6.  Benzoxazines. II. Synthesis, conformational analysis, and structure--activity relationships of 3,4-dihydro-2H-1,4-benzoxazine-8-carboxamide derivatives as potent and long-acting serotonin-3 (5-HT3) receptor antagonists.

Authors:  T Kuroita; N Marubayashi; M Sano; K Kanzaki; K Inaba; T Kawakita
Journal:  Chem Pharm Bull (Tokyo)       Date:  1996-11       Impact factor: 1.645

7.  Mechanisms of resistance to PARP inhibitors--three and counting.

Authors:  Tito Fojo; Susan Bates
Journal:  Cancer Discov       Date:  2013-01       Impact factor: 39.397

8.  RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.

Authors:  Anna Mizutani; Yoko Yashiroda; Yukiko Muramatsu; Haruka Yoshida; Tsubasa Chikada; Takeshi Tsumura; Masayuki Okue; Fumiyuki Shirai; Takehiro Fukami; Minoru Yoshida; Hiroyuki Seimiya
Journal:  Cancer Sci       Date:  2018-10-20       Impact factor: 6.716

9.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

Review 10.  Successes and Challenges of PARP Inhibitors in Cancer Therapy.

Authors:  Tiffany K Ricks; Haw-Jyh Chiu; Gwynn Ison; Geoffrey Kim; Amy E McKee; Paul Kluetz; Richard Pazdur
Journal:  Front Oncol       Date:  2015-10-14       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.